1. Home
  2. MPB vs CSTL Comparison

MPB vs CSTL Comparison

Compare MPB & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$31.07

Market Cap

797.6M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$24.90

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
CSTL
Founded
1868
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
797.6M
806.3M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
MPB
CSTL
Price
$31.07
$24.90
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$37.00
$47.17
AVG Volume (30 Days)
109.8K
398.2K
Earning Date
04-22-2026
05-04-2026
Dividend Yield
2.82%
N/A
EPS Growth
N/A
N/A
EPS
2.55
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$30.84
$2.42
Revenue Next Year
$9.45
$12.69
P/E Ratio
$12.26
N/A
Revenue Growth
N/A
3.66
52 Week Low
$22.50
$14.59
52 Week High
$35.22
$44.28

Technical Indicators

Market Signals
Indicator
MPB
CSTL
Relative Strength Index (RSI) 41.40 26.58
Support Level $28.12 $24.89
Resistance Level $31.75 $34.97
Average True Range (ATR) 0.82 1.02
MACD -0.10 0.13
Stochastic Oscillator 29.52 4.41

Price Performance

Historical Comparison
MPB
CSTL

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: